Effect of Extending the Duration of Prequit Treatment With Varenicline on Smoking Abstinence
A Randomized Clinical Trial

Larry W. Hawk Jr, PhD; Stephen T. Tiffany, PhD; Craig R. Colder, PhD; Rebecca L. Ashare, PhD; Jennifer M. Wray, PhD; Rachel F. Tyndale, PhD; Thomas H. Brandon, PhD; Martin C. Mahoney, MD, PhD

Abstract

IMPORTANCE Even with varenicline, the leading monotherapy for tobacco dependence, smoking abstinence rates remain low. Preliminary evidence suggests that extending the duration of varenicline treatment before quitting may increase abstinence.

OBJECTIVE To test the hypotheses that, compared with standard run-in varenicline treatment (1 week before quitting), extended run-in varenicline treatment (4 weeks before quitting) reduces smoking exposure before the target quit date (TQD) and enhances abstinence, particularly among women.

DESIGN, SETTING, AND PARTICIPANTS This double-blind, randomized, placebo-controlled clinical trial enrolled participants from October 2, 2017, to December 9, 2020, at a single-site research clinic in Buffalo, New York. Of 1385 people screened, 320 adults reporting smoking 5 or more cigarettes per day (CPD) were randomized and followed up for 28 weeks. Data were analyzed from August 2021 to June 2022.

INTERVENTIONS In the pre-TQD period (weeks 1-4), the extended run-in group received 4 weeks of varenicline; the standard run-in group received 3 weeks of placebo followed by 1 week of varenicline. Both groups received open-label varenicline during weeks 5 to 15 and brief quit counseling at 6 clinic visits.

MAIN OUTCOMES AND MEASURES The primary outcome consisted of cotinine-verified (at end of treatment [EOT]) self-reported continuous abstinence from smoking (in CPD) during the last 4 weeks of treatment. Secondary outcomes included bioverified self-report of continuous abstinence at the 6-month follow-up and percentage of reduction in self-reported smoking rate during the prequit period (week 1 vs week 4).

RESULTS A total of 320 participants were randomized, including 179 women (55.9%) and 141 men (44.1%), with a mean (SD) age of 53.7 (10.1) years. Continuous abstinence during the final 4 weeks of treatment (weeks 12-15; EOT) was not greater in the extended run-in group (64 of 163 [39.3%]) compared with the standard run-in group (57 of 157 [36.3%]; odds ratio [OR], 1.13 [95% CI, 0.72-1.78]), nor was the hypothesized group × sex interaction significant (OR, 0.52 [95% CI, 0.21-1.28]). Similar nonsignificant results were obtained for continuous abstinence at the 6-month follow-up. The mean (SE) decrease in self-reported smoking rate during the prequit period was greater in the extended run-in group (−38.8% [2.8%]) compared with the standard run-in group (−17.5% [2.7%]).

(continued)
Abstract (continued)

CONCLUSIONS AND RELEVANCE Among adult daily smokers, extending the duration of prequit varenicline treatment beyond the standard 1-week run-in period reduced prequit smoking exposure but, more importantly, did not significantly improve continuous abstinence rates.

TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT03262662

Introduction

Since 2006, varenicline has offered the most effective monotherapy for smoking cessation.\(^1\)\(^-\)\(^3\) However, long-term abstinence rates with varenicline remain low (20%-25% at 6 months or more).

One approach to improving outcomes is to target a treatment’s putative mechanisms of action.\(^4\)\(^-\)\(^7\) As a dual agonist and antagonist of nicotinic receptors, varenicline should decrease smoking even before a quit attempt; in learning theory terms, it should promote extinction of smoking behavior as a consequence of decreased reinforcement. Consistent with the hypothesis that varenicline reduces smoking reinforcement, varenicline has reduced nicotine self-administration in rats in a dose-dependent manner.\(^8\)\(^,\)\(^9\) However, extinction learning requires numerous trials and does not generalize well across contexts.\(^10\)\(^-\)\(^14\) Thus, the standard 1-week run-in period for varenicline (during which the dose is titrated) is likely insufficient to maximize extinction. Indeed, the results of placebo-controlled studies of people who are not actively trying to quit smoking suggest that it takes 2 to 3 weeks of varenicline administration to reduce smoking rate and biochemical exposure.\(^15\)\(^-\)\(^17\)

These findings suggest that the efficacy of varenicline could be enhanced by preloading,\(^18\)\(^,\)\(^19\) or increasing the duration of medication provided before the target quit date (TQD). The results of 2 preliminary randomized clinical trials\(^20\)\(^,\)\(^21\) (RCTs) support this hypothesis. In both trials, extended run-in groups exhibited greater reductions in pre-TQD smoking (without accompanying increases in craving or withdrawal) and nominally higher rates of smoking abstinence at the end of treatment (EOT) relative to standard run-in conditions. Although the results were encouraging, both studies had critical limitations: they were small (100 and 60 participants), used lenient\(^21\) or no\(^20\) bioverification, and had only 3 months of follow-up. Results of a subsequent larger trial\(^22\) (242 participants) suggesting an advantage of extended run-in varenicline treatment are difficult to interpret because participants were instructed to reduce pre-TQD smoking by more than 50%, resulting in considerable pre-TQD attrition, particularly in the standard run-in condition.

The primary aim of the present RCT was to rigorously test the hypothesis that extended run-in varenicline treatment produces better smoking abstinence rates than standard varenicline therapy. The study used a substantially larger sample (N = 320) to provide adequate statistical power, used cotinine levels (which reflect past-week exposure to nicotine) to provide stringent bioverification of self-reported continuous abstinence, and followed up participants for 6 months after the TQD.

The study was also powered to evaluate candidate moderators, specifically sex. Although women generally have lower rates of long-term abstinence than men,\(^23\)\(^,\)\(^24\) women exhibit a greater response to varenicline (relative to placebo) than men.\(^25\) In a pilot study,\(^21\) only women showed greater pre-TQD reductions in smoking exposure and greater postquit abstinence rates with extended run-in varenicline treatment (relative to standard varenicline treatment). Replication of those preliminary findings could be of considerable practical importance for helping women quit smoking.
Methods

The trial protocol and statistical analysis plan for this RCT are provided in Supplement 1. The study was conducted in accordance with the ethical principles of the Declaration of Helsinki and was approved by the institutional review boards of the University at Buffalo, Buffalo, New York (where data were collected) and the University of Toronto, Toronto, Ontario (where biological assays were performed). All participants provided written informed consent. The study followed the Consolidated Standards of Reporting Trials (CONSORT) reporting guideline.

Study Design

This RCT used a 2-group, balanced, randomized, double-blind, placebo-controlled, parallel-group design (a trial design schematic is provided in the trial protocol, section 5, in Supplement 1). Groups were distinguished by duration of varenicline treatment before the TQD (ie, run-in duration). The group with extended run-in received 4 weeks of varenicline before TQD. The group with standard run-in received 3 weeks of placebo, followed by the standard 1-week pre-TQD varenicline run-in treatment. Both groups received 11 weeks of post-TQD varenicline treatment and brief quit counseling.

Randomization

Participants were randomized by the statistician (C.R.C.) in small blocks (2:2) via prespecified tables implemented in REDCap. Randomization was stratified within self-reported sex (an a priori hypothesized moderator, men vs women) and race and ethnicity (non-Hispanic White vs all other racial and ethnic groups); both variables were collected per National Institutes of Health policy.

Recruitment and Participants

Adult smokers of combustible cigarettes who reported living within 50 miles from the University at Buffalo were recruited (beginning September 2017) through advertisements (radio, social media), recruitment databases (state Quitline, ResearchMatch.org), and a project website until the target sample size of 320 participants was enrolled. Inclusion criteria included smoking 10 or more cigarettes per day (CPD) for at least 6 months and an expired-air carbon monoxide level greater than 7 ppm at intake (to reduce exclusion of Black participants, the CPD criterion was reduced to ≥5 and the carbon monoxide criterion was eliminated in November 2019), motivation to quit smoking, and 18 to 70 years of age. Exclusion criteria included use of other tobacco and/or nicotine products in the past 7 days or use of cessation medication in the past 14 days, lifetime diagnosis of schizophrenia or bipolar disorder, current use of antipsychotic medication, suicidal ideation in the past year, current major depression, moderate-to-severe risk of involvement with illicit or nonmedical prescription drug use, and pregnancy. For additional details, see the trial protocol, section 6, in Supplement 1. Participant disposition is summarized in Figure 1, and demographic and smoking characteristics are presented in the Table. Participants were enrolled from October 2, 2017, to December 9, 2020.

Study Procedures

After an initial telephone screen, participants completed an intake visit (at which participants provided written informed consent), a baseline laboratory visit (discontinued March 2020 owing to the SARS-CoV-2 pandemic; data are reported elsewhere), and a baseline week of daily smartphone assessments. Participants made 6 clinic visits to the University of Buffalo–based research clinic at baseline (week 0), during the pre-TQD drug manipulation phase (weeks 1 and 3), on the TQD (week 4), and at weeks 6 and 8. Follow-up visits occurred at week 15 (EOT) and week 28 (6 months). All visits included assessment of vital signs; measurement of expired-air carbon monoxide level (Bedfont Inc); self-reports of smoking rate, craving, affect, withdrawal, and adverse events; and collection of a saliva sample for cotinine, trans-3′-hydroxycotinine (3HC), and varenicline assessment.
Study medication and counseling (described below) were provided at each clinic visit. Participants were compensated as much as US $598 for completing study visits and measures.

**Interventions**

**Pharmacotherapy**

Pfizer Inc provided varenicline and identically appearing placebo, which was dispensed at each clinic visit (except during the COVID-19 shutdown [April 1 to June 15, 2020], when dispensing occurred less frequently). Participants were initially dispensed a 1-week supply of tablets labeled 0.5 mg to be taken orally (1 morning tablet for days 1-3 and 1 morning and 1 evening tablet for days 4-7 consisting of varenicline for the extended run-in group and placebo for the standard run-in group). During weeks 2 and 3 of the medication manipulation phase, participants were given 1.0-mg tablets to be taken twice daily (varenicline for the extended run-in group and placebo for the standard run-in group). To maintain blinding and allow titration for participants assigned to the standard run-in group, during week 4 all participants were provided with 4 tablets/d (2 for morning and 2 for evening) as a taper.

**Figure 1. Flow Diagram of Trial Recruitment and Eligibility Evaluation, Intervention Randomization, Treatment and Follow-up, and Analysis**
evening) marked 0.5 mg (varenicline for the extended run-in group; for the standard run-in group, 1 of 2 morning tablets was varenicline and, for days 4-7, 1 of 2 evening tablets was varenicline).

Beginning with the TQD, all participants were dispensed open-label 1.0-mg varenicline twice daily.

Counseling
Participants received brief (approximately 15 minutes) behavioral counseling per a treatment manual adapted from prior studies. Counseling focused on honing quit motivation; preventing or managing adverse effects, stress, and smoking triggers; and relapse prevention. To promote continued smoking and foster extinction, participants were instructed to smoke as usual during weeks 1 to 3. Brief (approximately 5-minute) telephone check-ins occurred during weeks 5 and 11.

Outcome Measures
Our prespecified primary outcome was continuous abstinence at EOT (no self-reported cigarette smoking [not even a puff] during the final 4 weeks of treatment [weeks 12-15]), bioverified with EOT.

| Table. Baseline Participant Characteristics for Each Run-in Group and Each Sex × Group Condition |
|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|
| Characteristic                      | Participant groupa | Women                                                                 | Men                                                                 | All                                                                 |
|                                  | Standard run-in (n = 68) | Extended run-in (n = 73) | Standard run-in (n = 89) | Extended run-in (n = 90) | Standard run-in (n = 157) | Extended run-in (n = 163) |
| Age, mean (SD), y                 | 54.2 (9.3) | 54.2 (9.8) | 53.5 (10.0) | 53.8 (10.3) | 52.7 (10.9) | 53.2 (10.9) |
| Race                               |                |                |                |                |                |                |
| Black or African American           | 10 (14.7) | 9 (12.3) | 24 (27.0) | 24 (26.7) | 34 (21.7) | 33 (20.2) |
| White                              | 55 (80.9) | 59 (80.8) | 63 (70.8) | 63 (70.0) | 118 (75.2) | 122 (74.8) |
| Otherb                            | 3 (4.4) | 5 (6.8) | 2 (2.2) | 3 (3.3) | 5 (3.2) | 8 (4.9) |
| Hispanic ethnicity                 | 2 (2.9) | 1 (1.4) | 2 (2.2) | 3 (3.3) | 4 (2.5) | 4 (2.5) |
| Educational level past high schoolc | 47 (72.3) | 47 (67.1) | 67 (77.0) | 68 (77.3) | 114 (75.0) | 115 (72.8) |
| Employed full-timeed               | 34 (52.3) | 33 (48.5) | 37 (42.5) | 38 (43.2) | 71 (46.7) | 71 (45.5) |
| Income ≥$50 000e                    | 39 (63.9) | 40 (60.6) | 43 (51.8) | 40 (49.4) | 82 (56.9) | 80 (54.4) |
| Married or living with partnerf    | 37 (57.8) | 41 (57.8) | 47 (54.0) | 45 (51.7) | 84 (55.6) | 86 (54.4) |
| BMI, mean (SD), kg                 | 96.2 (20.1) | 93.8 (22.5) | 83.5 (23.2) | 79.0 (22.8) | 89.0 (22.7) | 85.7 (21.6) |
| Age first smoked daily, mean (SD), y | 18.7 (3.6) | 17.9 (3.6) | 18.5 (3.5) | 18.8 (3.5) | 18.6 (3.6) | 18.4 (3.6) |
| Duration of daily smoking, mean (SD), y | 33.7 (11.4) | 35.1 (11.2) | 35.8 (9.5) | 35.3 (9.7) | 34.9 (10.4) | 35.2 (10.3) |
| CPD in past 6 mo, mean (SD)        | 35.5 (2.2) | 35.5 (1.8) | 35.1 (1.9) | 36.1 (1.8) | 6.2 (1.6) | 6.2 (1.7) |
| FTCD score, mean (SD)h             | 25 (39.1) | 25 (35.2) | 50 (57.5) | 55 (62.5) | 75 (49.7) | 80 (50.3) |
| Smokes menthol cigarettesi         | 16 (32.7) | 14 (29.8) | 23 (33.8) | 30 (47.6) | 39 (33.3) | 44 (40.0) |
| Lives with another smokeri          | 27.7 (14.0) | 28.4 (12.7) | 27.1 (15.6) | 28.1 (13.2) | 27.4 (14.9) | 28.2 (13.0) |
| Salivary cotinine level, mean (SD), ng/mL | 308.8 (169) | 319.8 (172) | 314.0 (160) | 305.6 (146) | 311.8 (164) | 312.0 (158) |
| NMR, mean (SD)                     | 0.42 (0.32) | 0.47 (0.34) | 0.52 (0.50) | 0.62 (0.42) | 0.48 (0.43) | 0.55 (0.39) |
| No. of prior quit attempts, mean (SD) | 4.2 (3.2) | 4.6 (3.3) | 4.6 (3.2) | 4.1 (3.0) | 4.4 (3.2) | 4.4 (3.1) |
| Longest quit duration >8 wkj       | 37 (56.9) | 35 (49.3) | 51 (38.6) | 53 (60.2) | 88 (57.9) | 88 (55.3) |

Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); CO, carbon monoxide; CPD, cigarettes per day; FTCD, Fagerstrom Test of Cigarette Dependence; NMR, nicotine metabolite ratio.

a Unless otherwise indicated, data are expressed as No. (%) of participants. To convert cotinine level to nmol/L, multiply by 5.675.

b Includes American Indian or Alaska Native, more than 1 race or ethnicity, and other race or ethnicity.

c Data were missing for 10 of 320 participants (3.1%).

d Data were missing for 9 of 320 participants (2.8%).


November 11, 2022  5/14

Downloaded From: https://jamanetwork.com/ on 09/30/2023
salivary cotinine level of 15 ng/mL or less (to convert to nmol/L, multiply by 5.675). Continuous abstinence at the 6-month follow-up (no self-reported smoking during weeks 12-28, cotinine level ≤15 ng/mL at EOT and 6 months) and percentage reduction in smoking behavior (CPD) during the prequit phase of the study were prespecified secondary outcomes. Self-reported smoking was assessed via timeline follow-back interview.37 Salivary cotinine and 3HC (used for the ratio of 3HC to cotinine, or the nicotine metabolite ratio) were assayed using liquid chromatography–mass spectrometry (lower limit of quantification, 1 ng/mL).38-40 Unregistered outcomes included cotinine concentrations during the prequit period (weeks 0, 1, 3, and 4); bioverified 7-day point-prevalence abstinence at weeks 6, 8, 15 (EOT), and 28 (6 months); and the following measures at all clinic visits: self-report measures of current craving41 and past-week nicotine withdrawal,42 pill count adherence, and adverse events (assessed via a 32-item symptom checklist21,36,43 and open-ended queries).

**Sample Size Calculation**
A priori analysis used Monte Carlo simulations and abstinence rates from the pilot study21 and focused on the primary outcome of continuous abstinence at EOT with 2-tailed α = .05 and power of 0.90. With 320 participants, the study was powered to detect an increase in abstinence rate of at least 13% in the extended run-in group, compared with an expected 40% abstinence rate in the standard run-in group. With respect to sex moderation, the study was powered to detect a difference of increased abstinence of 32% in the extended run-in group for women compared with a decline in abstinence rate of 10% in extended run-in group for men, as previously observed.21

**Statistical Analysis**
Data were analyzed from August 2021 to June 2022. Analyses (conducted in SPSS, version 28 [IBM Corp] and Mplus, version 8.8 [Muthén & Muthén]) included run-in group, sex, and their interaction. Significance level was 2-tailed α = .05. The primary outcome, continuous smoking abstinence during the final 4 weeks of treatment (bioverified at EOT), was analyzed based on intention-to-treat (N = 320) via logistic regression; participants with missing data were considered smokers (results of supplemental multiple imputation analyses are described below). Continuous abstinence at 6 months (a secondary outcome) was analyzed similarly. Percentage reduction in self-reported smoking rate (CPD) during the prequit period (a secondary outcome) was analyzed in a group × sex analysis of variance.

**Results**

**Baseline Characteristics**
A total of 320 participants were randomized, including 179 women (55.9%) and 141 men (44.1%), with a mean (SD) age of 53.7 (10.1) years. The Table provides demographic and smoking characteristics for all treatment groups and groups by sex (eAppendix 1, eTable A1, in Supplement 2). Participants reported smoking a mean (SD) of 18.1 (7.2) CPD and were moderately nicotine dependent (mean [SD] Fagerstrom Test of Cigarette Dependence score, 5.5 [2.0]). Women had a faster nicotine metabolite ratio (mean [SD], 0.57 [0.46] vs 0.44 [0.33]), lower body weight (mean [SD], 81.2 [21.0] vs 95.0 [21.3] kg), fewer CPD (mean [SD], 16.8 [6.2] vs 19.9 [8.1]), and more years of education (educational attainment beyond high school, 135 [75.4%] vs 94 [66.7%]) than men.

**Participants**
As shown in Figure 1, retention was comparable between the extended and standard run-in groups at EOT (127 of 163 [77.9%] and 126 of 157 [80.3%]) and at 6 months (124 of 163 [76.1%] and 121 of 157 [77.1%]; P > .7). Retention at 6 months was somewhat lower among men in the extended run-in group compared with men in the standard run-in group (48 of 73 [65.8%] vs 53 of 68 [77.9%]) and compared with women in the extended run-in group (76 of 90 [84.4%]) and women in the standard run-in group (68 of 89 [76.4%]) (group × sex P = .17 at EOT and P = .04 at 6 months).
Primary Outcome

Contrary to our hypothesis, continuous abstinence at EOT (Figure 2) was not significantly greater in the extended compared with the standard run-in group (64 of 163 [39.3%] vs 57 of 157 [36.3%]; odds ratio [OR], 1.13 [95% CI, 0.72-1.78]; P = .60) and did not significantly differ between women (63 of 179 [35.2%]) and men (58 of 141 [41.1%]) (OR, 1.29 [95% CI, 0.82-2.02]; P = .28). Most importantly, the hypothesized group × sex interaction was not significant overall (OR, 0.52 [95% CI, 0.21-1.28]; P = .55), nor was the post-hoc test of the run-in group effect among women (OR, 1.53 [95% CI, 0.83-2.84]; P = .18) or men (OR, 0.79 [95% CI, 0.40-1.54]; P = .49).

Secondary Outcomes

Abstinence at 6 Months

The results for continuous abstinence at 6 months were similar to those obtained at EOT (Figure 3). We observed no significant effects in run-in group (OR, 1.29 [95% CI, 0.75-2.23]; P = .36), sex (OR, 1.46 [95% CI, 0.85-2.51]; P = .18), or group × sex interaction (OR, 0.50 [95% CI, 0.17-1.49]; P = .21). Similarly, post-hoc tests of the run-in group effect among women (OR, 1.83 [95% CI, 0.84-4.02]; P = .13) and men (OR, 0.91 [95% CI, 0.42-1.97]; P = .81) were not significant.

Supplemental analyses of continuous abstinence at EOT and 6 months that incorporated covariates, considered moderators, and used multiple imputation for missingness all yielded similar results; there were no statistically significant main effects or interactions involving the run-in group
(eAppendix 2 in Supplement 2). The same was true in analyses of 7-day point prevalence abstinence at EOT and 6 months (eAppendix 2 in Supplement 2).

**Percentage Reduction in Pre-TQD Smoking Rate**
As hypothesized, although both groups self-reported reducing their smoking rate (in CPD) during the prequit period (Figure 4), the reduction was greater in the extended run-in group compared with the standard run-in group (mean [SE], −38.8% [2.8%] vs −17.5% [2.7%]; \( P < .001 \)). Although women tended to report greater reduction in pre-TQD CPD compared with men (mean [SE], −31.4% [2.5%] vs −24.9% [2.9%]; \( P = .09 \)), there was no evidence that the group difference varied between men (means [SE], −35.6% [4.2%] for extended and −14.1% [4.1%] for standard groups) and women (mean [SE], −42.0% [3.5%] for extended and −20.9% [3.7%] for standard groups; group × sex interaction; \( P = .95 \)). Supplemental analyses of week-to-week changes in prequit CPD and cotinine levels yielded comparable results (eAppendix 3 in Supplement 2).

**Unregistered Outcomes**

**Craving and Withdrawal**
Consistent with our hypothesis, craving at week 4 (TQD) was greater in the standard compared with the extended run-in group, a difference that was stronger among women than men. From weeks 4 to 8, withdrawal increased in the standard run-in group but declined in the extended run-in group, a pattern that tended to be stronger among women than men (details in eAppendix 4 in Supplement 2).

**Adherence**
Pill count adherence (mean [SD], 82.5% [29.2%]; 244 of 318 [76.7%] of the sample were ≥80% adherent) was assessed during the 15-week treatment period. Results did not vary as a function of group, sex, or their interaction (eAppendix 5 in Supplement 2).

**Adverse Events**
Symptom reports were generally as expected for varenicline (details are provided in eAppendix 6 in Supplement 2). During the run-in manipulation period (weeks 1-3), nausea and abnormal dreams were more common among participants in the extended run-in group vs those in the standard run-in group; these differences were not significant once the standard run-in group began active varenicline therapy. Similar patterns were observed for multiple gastrointestinal tract symptoms, other sleep problems, and dizziness. Consistent with our hypotheses, the group difference in nausea was primarily driven by women. Serious adverse events were rare (3 in each run-in group) and deemed unexpected and unrelated to study medication (details in eAppendix 6 in Supplement 2).
Discussion

Previous large RCTs have demonstrated that both standard and extended run-in varenicline treatments enhance smoking abstinence relative to placebo treatment, but these trials do not address the question of whether extended run-in varenicline treatment is better than standard varenicline treatment. From the perspective of extinction learning, a longer duration of pre-TQD varenicline treatment would allow numerous prequit opportunities for participants to experience a reduction of reinforcement while smoking, resulting in reduced prequit smoking exposure (without increasing craving or withdrawal) and improved postquit abstinence rates.

As hypothesized in the present RCT, the extended run-in group exhibited reduced smoking exposure during the prequit period (i.e., lower self-reported smoking rate and cotinine levels) and attenuated peri-TQD craving and withdrawal relative to the standard run-in group. Rates of attrition were typical, albeit somewhat lower at 6 months for men in the extended run-in group. Overall, from a mechanism and process perspective, the trial results were largely as expected and supported the internal validity of the study.

However, rates of bioverified, self-reported continuous smoking abstinence at the 3-month (EOT; the primary outcome) and 6-month follow-ups were not significantly higher for extended run-in varenicline treatment. Thus, preliminary support for extended prequit varenicline treatment observed in a pair of pilot RCTs funded by Pfizer Inc., was not substantiated in the present, much larger trial (320 participants vs 100 for Hajek et al. and 60 for Hawk et al.). Although abstinence rates in the standard run-in condition were somewhat lower than estimated based on the pilot study, they were similar to rates observed in recent large-scale varenicline trials.

Based on the pilot RCT and other evidence of sex differences in the neurobiology and behavioral pharmacology of smoking and of smoking cessation, we hypothesized that the extended run-in varenicline treatment would outperform standard run-in treatment, specifically among women. Although the rates of abstinence were in the hypothesized direction, the interaction was not statistically significant at EOT or at 6 months. Moreover, there was no evidence that sex moderated the run-in group effect on pre-TQD changes in smoking behavior (CPD) or exposure (cotinine level). These data argue against the a priori hypothesis that pre-TQD varenicline treatment would extinguish smoking to a greater extent among women than men.

Craving and withdrawal (unregistered but commonly reported outcomes in varenicline trials) were moderated by sex in a manner consistent with the hypothesized greater benefit for women. It is possible that extended run-in varenicline treatment potentiates, at least among women, the mechanisms of action recently reported for standard varenicline (reduced craving and negative affect). However, in the present study, this did not translate into a significant enhancement of smoking abstinence. The present study may have been underpowered to detect the effect on dichotomous abstinence, because our a priori power analysis was based on a preliminary study with a small sample size, limiting the precision of the estimate. Given that women generally have more difficulty maintaining long-term abstinence than men, it may be worthwhile to test these hypotheses in the context of a larger, women-only multisite trial.

Limitations

In addition to the concern about statistical power just mentioned, additional limitations merit consideration. First, internal validity could have been compromised by the confounding of the duration of prequit varenicline treatment and total duration of varenicline treatment. That is, as in prior studies of medication preloading, the extended run-in group received a longer total duration of varenicline treatment (15 weeks) than did the standard run-in group (12 weeks). However, because even doubling the duration of postquit varenicline treatment from 11 to 23 weeks did not enhance long-term abstinence in a large, recent trial, any effects of extended prequit varenicline on abstinence—had they been statistically significant—were unlikely to be accounted for by the total duration of treatment. Second, although we followed recommendations to relax
enrollment eligibility criteria in comparison with earlier trials, external validity remained limited by the exclusion of participants with conditions that are comorbid with smoking, including depression, schizophrenia, and problematic use of illicit and prescription drugs.53 Third, the a priori focus on a relatively short follow-up period (3 months) for the primary abstinence outcome, although common in varenicline trials1,45,48,54,55 and supplemented by a 6-month follow-up, is also a limitation.

Conclusions

In this RCT, although extended run-in varenicline treatment reduced pre-TQD smoking rate to a greater extent than standard run-in varenicline treatment, it did not significantly enhance rates of smoking abstinence at the 3- or the 6-month follow-up. Thus, on average, adult daily smokers did not significantly benefit from extending the duration of prequit treatment with varenicline beyond the standard 1-week run-in period.
which he owns restricted stock. Dr Mahoney reported receiving nonfinancial support from Pfizer Inc during the conduct of the study and serving as former speaker/content expert on smoking cessation for Pfizer Inc outside the submitted work. No other disclosures were reported.

**Funding/Support:** This work was supported primarily by grant R01CA206193 from the NCI (Drs Hawk, Tiffany, and Mahoney); by grants UL1TR001412 (University of Buffalo) and UL1TR002001 (University of Rochester) from the NCATS/NIH; by the Canada Research Chair in Pharmacogenetics program (Dr Tyndale); and by foundation grant FDN-IS4294 from the Canadian Institutes of Health Research (Dr Tyndale). Pfizer Inc provided free study medication (active varenicline and placebo).

**Role of the Funder/Sponsor:** The sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

**Data Sharing Statement:** See Supplement 3.

**Additional Contributions:** Constance Duerr, MS, and Jennifer Adams, MSW, served as project coordinators; Louise Cooper, RPh, and Denise Swiatek, PharmD, as study pharmacists; and Eugene Maguin, PhD, as data analyst. Postdoctoral fellows Nicolas Schlenz, PhD, and Julie Gass, PhD, graduate assistants Sarah Tonkin, MA, Robert Cooper, MA, Schuyler Lawson, MA, Adam Ferkin, MA, Jennifer Betts, MA, Lauren Rodriguez, MA, and Nolan Ramer, MA; recruitment specialist Amanda Ziegler, RN; research support specialist Deonna Coleman, MA; and many undergraduate research assistants contributed to visit preparation, data collection, and data reduction. All named contributors were compensated for their roles. We also thank the community members from Western New York State who participated in this clinical trial.

**REFERENCES**


**SUPPLEMENT 1.**

Trial Protocol and Statistical Analysis Plan
SUPPLEMENT 2.
eAppendix 1. Supplemental Information on Categorical Participant Characteristics
eAppendix 2. Supplemental Abstinence Analyses
eAppendix 3. Supplemental Analyses of Reduction in Smoking Exposure Across the Prequit Period
eAppendix 4. Craving and Withdrawal
eAppendix 5. Pill Count Medication Adherence
eAppendix 6. Symptom Report Data

SUPPLEMENT 3.
Data Sharing Statement